2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, Neutropenia, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

5596 Clinical and prognostic significance of unclassifiable myelodysplastic syndromes (MDS-U) and MDS without gene mutations

Carolina Perrone Marques, MD, Eduardo Cerello Chapchap, MD2, Frederico Honorato Honorato Jr, MD3, Aline Raposo Nishimoto, MD4, Alexandre Eiji Eiji Kayano, MD5, Tarcila Santos Datoguia, MD6, Jade Nascimento, MD7, Kira Bucci, MD8, Juliana Dall Agnol Rocha, MD9, Luana Nobrega, MD10, Paloma Martinho Resende, MD11, André Dias Américo, MD12, Amanda Inácio Dias Ennes, MD13, Elvira Velloso Sr, Dr14, Nelson Hamerschlak Sr, MD PhD15, Fabio Pires S Santos, MD, PhD16
1 Einstein Hospital Israelita, Sao Paulo, Brazil
2 Einstein Hospital Israelita, Sao Paulo, Brazil
3 Einstein Hospital Israelita, Sao Paulo, Brazil
4 Einstein Hospital Israelita, Sao Paulo, Brazil
5 Einstein Hospital Israelita, Sao Paulo, Brazil
6 Einstein Hospital Israelita, Sao Paulo, Brazil
7 Einstein Hospital Israelita, Sao Paulo, Brazil
8 Einstein Hospital Israelita, Sao Paulo, Brazil
9 Einstein Hospital Israelita, Sao Paulo, Brazil
10 Einstein Hospital Israelita, Sao Paulo, Brazil
11 Einstein Hospital Israelita, Sao Paulo, Brazil
12 Hospital Beneficência Portuguesa, São paulo, Brazil
13 Einstein Hospital Israelita, Sao Paulo, Brazil
14 Einstein Hospital Israelita, São Paulo, Brazil
15 Einstein Hospital Israelita, Sao Paulo, Brazil
16 Einstein Hospital Israelita, Sao Paulo, Brazil

Introduction: Myelodysplastic syndromes (MDS) are clonal myeloid neoplasms, yet a subset of patients has no detectable driver mutations on current next-generation sequencing (NGS) panels. The clinical significance of this group remains uncertain. Similarly, morphologically unclassifiable cases (MDS-U) remain poorly characterized at the genomic and prognostic levels.

Methods: We analyzed 2,435 MDS patients with sequencing data (53-gene panel) from the IPSS-M cohort (MDS International Working Group). The analysis was restricted to confirmed MDS cases after excluding MDS/MPN overlap neoplasms and cases with prior leukemic transformation. We prespecified twoTwo orphan groups were pre-specified (driver-negative, n=113; and MDS-U, n=81) and compared with classifiable, driver-positive MDS (n=2,246). Outcomes were overall survival (OS) and leukemia-free survival (LFS), assessed using Kaplan-Meier/log-rank and Cox regression adjusted for IPSS-R. Transformation to acute myeloid leukemia (AML) was analyzed using cumulative incidence with competing risks (non-leukemic death as the competing event) and compared using Gray's test. Cases with unsequenced genes were excluded (NA was never imputed as wild-type).

Results: The two orphan groups rarely overlapped (only 5 double-orphan cases), establishing driver-negativity and unclassifiability as distinct phenomena. The driver-negative group was younger (median 66 vs 72 years), more frequently female (60% vs 38%), and had no complex karyotypes (0% vs 11%); 58% had a normal karyotype, and del(5q) was the most frequent abnormality (15%). Median OS was 64 vs 39 months (log-rank p=0.0002), with a hazard ratio (HR) of 0.57 (95% CI 0.39-0.82) adjusted for IPSS-R; LFS was similarly superior (HR 0.55, 0.38-0.80). At 10 years, only 8% of driver-negative patients transformed to AML versus 27% in the reference group (Gray p=0.001), whereas non-leukemic death did not differ (p=0.39). In a sensitivity analysis restricted to driver-negative cases with a normal karyotype (n=65), the lower transformation to AML persisted (5% vs 27%, Gray p=0.010). Roughly 54% of driver-negative cases (61/113) did not present with any cytogenetic abnormality, excess blasts, or ring sideroblasts, and the MDS diagnosis was based on morphological dysplasia alone; among these "dysplasia-only" patients, only 1 of 48 evaluable (2%) progressed to AML, while the remaining deaths were non-leukemic. In contrast, MDS-U harbored a driver in 94% of cases, with no gene enriched after false discovery rate (FDR) correction, and no significant survival difference from classifiable MDS (OS 27 vs 39 months, p=0.92).

Conclusions: Driver-negative MDS constitutes a genuinely indolent subgroup, independent of IPSS-R, in which nearly half of cases lack any objective marker beyond dysplasia, suggesting that these patients need dedicated diagnostic evaluation and surveillance rather than treatment. In contrast, MDS-U does not appear to correspond to a distinct genomic or prognostic entity.

Carolina Perrone Marques, MD: No relevant conflicts of interest to declare.